Citadel Advisors’s Shuttle Pharmaceuticals SHPH Stock Holding History

Citadel Advisors’s Portfolio SHPH Stock Details SHPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-380	Closed	-$36.9K	–	14822
2025 Q1	$36.9K	Buy	+380	New	+$61.7K	﹤0.01%	12614

Other funds holding SHPH

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Citadel Advisors's SHPH Position: Q2 2025 in Review

Citadel Advisors sold out of Shuttle Pharmaceuticals (SHPH) in Q2 2025, closing a stake of 380 shares — an estimated $36.9K sold.

Citadel Advisors first reported a position in SHPH in Q1 2025 and held it in 1 quarter. The position peaked at $36.9K in Q1 2025. 3 funds tracked by Wall St. Rank hold SHPH as of Q2 2025.

Citadel Advisors reported no remaining Shuttle Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 380 Shuttle Pharmaceuticals shares in Q2 2025, an estimated $36.9K.
Citadel Advisors first reported a position in Shuttle Pharmaceuticals in Q1 2025 and held it in 1 quarter.
Citadel Advisors's Shuttle Pharmaceuticals position peaked at $36.9K in Q1 2025.
3 funds tracked by Wall St. Rank held Shuttle Pharmaceuticals as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.